Edwards Lifesciences Corp (EW) Stock Price & Analysis
Edwards Lifesciences Corp (EW) fell 1.42% to USD 82.63 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
EW last closed at USD 83.82; the session ranged USD 82.53–89.08 on volume of 9,263,588 shares. Market capitalization is $47.58B, with a 52-week range of USD 72.3–96.29 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 82.63 |
|---|---|
| Change | ▼ 1.42% (down) |
| Previous Close | USD 83.82 |
| Open | USD 88 |
| Day Range | USD 82.53 – 89.08 |
| 52-Week Range | USD 72.3 – 96.29 |
| Volume | 9,263,588 shares |
| Market Cap | $47.58B |
| Exchange | NYQ |
Technical Analysis (EW)
Nexqual's technical model rates EW "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.82 (neutral) |
| vs SMA50 | Below (USD 87.25) |
| MACD | -1.18 (negative) |
Analyst Ratings (EW)
Wall Street analysts rate EW "Buy" based on 25 analysts, with a mean price target of USD 100.36 (range USD 84–110), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 25 |
| Mean Target | USD 100.36 |
| High Target | USD 110 |
| Low Target | USD 84 |
| Buy / Hold / Sell | 20 / 7 / 0 |
Earnings (EW)
| Next Earnings Date | 2026-07-23 |
|---|---|
| EPS Estimate | USD 0.74 |
| Revenue Estimate | $1.68B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.78 vs est 0.74 ▲ beat |
| 2026-03-31 | USD 0.78 vs est 0.73 ▲ beat |
| 2025-12-31 | USD 0.58 vs est 0.62 ▼ miss |
| 2025-09-30 | USD 0.67 vs est 0.59 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (EW)
| Total Revenue | $6.51B |
|---|---|
| Revenue Growth (YoY) | +13.60% |
| Gross Margin | +77.84% |
| Operating Margin | +29.84% |
| Profit Margin | +15.43% |
| Debt / Equity | 6.81 |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (EW)
Nexqual rates Edwards Lifesciences Corp's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 78%, operating 30% |
| Balance Sheet | Strong — Debt/Equity 0.1x |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (EW)
| Insider Ownership | +0.18% |
|---|---|
| Institutional Ownership | +94.30% |
| Shares Outstanding | 575.80M |
| Float | 578.96M |
| Short % of Float | +2.27% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (EW)
Edwards Lifesciences Corp is led by Bernard J. Zovighian (age 57), CEO & Director, per Nexqual as of July 25, 2026 at 01:12 UTC.
| CEO & Director | Bernard J. Zovighian (age 57) |
|---|---|
| Corporate Vice President of Strategy & Corporate Development | Donald E. Bobo (age 63) |
| Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies | Daveen Chopra (age 46) |
| Corporate Vice President of EMEA, Canada, & Latin America | Annette Maria Bruls (age 54) |
| Corporate VP & CFO | Theodora Mistras (age 43) |
Major Backers & Investors (EW)
Notable institutional backers of Edwards Lifesciences Corp include Wellington Management, JPMorgan, FMR, LLC, according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 3.82% |
| JPMorgan | 3.78% |
| FMR, LLC | 2.52% |
| Jennison Associates LLC | 2.27% |
| Fidelity | 1.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 23.24% |
| BlackRock | 10.46% |
| State Street | 5.78% |
| BNY Mellon | 2.91% |
| Geode Capital | 2.28% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Edwards Lifesciences Corp's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
- It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
- The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
- It distributes its products through a direct sales force and independent distributors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BAX | Baxter International Inc. | USD 22.4 | ▲ 3.04% |
| BSX | Boston Scientific Corporation | USD 44.25 | ▲ 2.98% |
| RMD | ResMed Inc. | USD 195.27 | ▲ 1.22% |
| SYK | Stryker Corporation | USD 330.25 | ▲ 6.79% |
| BDX | Becton, Dickinson and Company | USD 156.36 | ▲ 2.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.